Operating Income (Loss) in USD of INOVIO PHARMACEUTICALS, INC. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
INOVIO PHARMACEUTICALS, INC. quarterly/annual Operating Income (Loss) history and change rate from Q2 2010 to Q3 2025.
  • INOVIO PHARMACEUTICALS, INC. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$21.2M, a 22.4% increase year-over-year.
  • INOVIO PHARMACEUTICALS, INC. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$89.7M, a 24.9% increase year-over-year.
  • INOVIO PHARMACEUTICALS, INC. annual Operating Income (Loss) for 2024 was -$112M, a 21.9% increase from 2023.
  • INOVIO PHARMACEUTICALS, INC. annual Operating Income (Loss) for 2023 was -$144M, a 46.2% increase from 2022.
  • INOVIO PHARMACEUTICALS, INC. annual Operating Income (Loss) for 2022 was -$268M, a 11.2% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

INOVIO PHARMACEUTICALS, INC. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$89.7M -$21.2M +$6.14M +22.4% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025
Q2 2025 -$95.9M -$23.1M +$10.1M +30.5% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025
Q1 2025 -$106M -$25.1M +$6.43M +20.4% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025
Q4 2024 -$112M -$20.4M +$7.02M +25.6% 01 Oct 2024 31 Dec 2024 10-K 18 Mar 2025
Q3 2024 -$119M -$27.3M +$8.21M +23.1% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025
Q2 2024 -$128M -$33.2M +$3.84M +10.4% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025
Q1 2024 -$131M -$31.5M +$12.5M +28.4% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025
Q4 2023 -$144M -$27.4M +$28.6M +51% 01 Oct 2023 31 Dec 2023 10-K 18 Mar 2025
Q3 2023 -$172M -$35.6M +$204K +0.57% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 -$173M -$37M +$67.1M +64.4% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 -$240M -$44M +$27.8M +38.7% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024
Q4 2022 -$268M -$55.9M +$49.6M +47% 01 Oct 2022 31 Dec 2022 10-K 06 Mar 2024
Q3 2022 -$317M -$35.8M +$24.2M +40.4% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$341M -$104M -$20.9M -25.2% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023
Q1 2022 -$320M -$71.7M -$19.2M -36.5% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023
Q4 2021 -$301M -$106M -$76.2M -260% 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2024
Q3 2021 -$225M -$60M -$23.6M -65% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022
Q2 2021 -$201M -$83.2M -$50M -151% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022
Q1 2021 -$151M -$52.6M -$27.3M -108% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022
Q4 2020 -$124M -$29.3M +$1.08M +3.56% 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2021
Q3 2020 -$125M -$36.3M -$12.4M -51.7% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021
Q2 2020 -$113M -$33.2M -$4.98M -17.7% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021
Q1 2020 -$108M -$25.2M +$3.3M +11.6% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021
Q4 2019 -$111M -$30.4M -$922K -3.13% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2021
Q3 2019 -$110M -$24M +$2.69M +10.1% 01 Jul 2019 30 Sep 2019 10-K 01 Mar 2021
Q2 2019 -$113M -$28.2M -$23M -442% 01 Apr 2019 30 Jun 2019 10-K 01 Mar 2021
Q1 2019 -$89.9M -$28.5M +$4.21M +12.9% 01 Jan 2019 31 Mar 2019 10-K 01 Mar 2021
Q4 2018 -$94.1M -$29.5M -$6.61M -28.9% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2020
Q3 2018 -$87.5M -$26.6M +$2.54M +8.71% 01 Jul 2018 30 Sep 2018 10-K 12 Mar 2020
Q2 2018 -$90M -$5.2M +$4.43M +46% 01 Apr 2018 30 Jun 2018 10-K 12 Mar 2020
Q1 2018 -$94.5M -$32.7M -$10.8M -49.3% 01 Jan 2018 31 Mar 2018 10-K 12 Mar 2020
Q4 2017 -$83.6M -$22.9M -$524K -2.35% 01 Oct 2017 31 Dec 2017 10-K 12 Mar 2019
Q3 2017 -$83.1M -$29.2M -$8.99M -44.5% 01 Jul 2017 30 Sep 2017 10-K 12 Mar 2019
Q2 2017 -$74.1M -$9.64M +$8.59M +47.1% 01 Apr 2017 30 Jun 2017 10-K 12 Mar 2019
Q1 2017 -$82.7M -$21.9M -$6.48M -42% 01 Jan 2017 31 Mar 2017 10-K 12 Mar 2019
Q4 2016 -$76.2M -$22.4M -$7.84M -53.9% 01 Oct 2016 31 Dec 2016 10-K 14 Mar 2018
Q3 2016 -$68.4M -$20.2M -$23.9M -641% 01 Jul 2016 30 Sep 2016 10-K 14 Mar 2018
Q2 2016 -$44.5M -$18.2M -$3.11M -20.5% 01 Apr 2016 30 Jun 2016 10-K 14 Mar 2018
Q1 2016 -$41.4M -$15.5M -$7.08M -84.6% 01 Jan 2016 31 Mar 2016 10-K 14 Mar 2018
Q4 2015 -$34.3M -$14.5M -$3.51M -31.9% 01 Oct 2015 31 Dec 2015 10-K 15 Mar 2017
Q3 2015 -$30.8M $3.73M +$12.1M 01 Jul 2015 30 Sep 2015 10-K 15 Mar 2017
Q2 2015 -$42.8M -$15.1M -$4.97M -48.9% 01 Apr 2015 30 Jun 2015 10-K 15 Mar 2017
Q1 2015 -$37.9M -$8.37M +$1.63M +16.3% 01 Jan 2015 31 Mar 2015 10-K 15 Mar 2017
Q4 2014 -$39.5M -$11M -$3.01M -37.6% 01 Oct 2014 31 Dec 2014 10-K 14 Mar 2016
Q3 2014 -$36.5M -$8.33M -$9.1M -1188% 01 Jul 2014 30 Sep 2014 10-K 14 Mar 2016
Q2 2014 -$27.4M -$10.2M -$4.48M -79% 01 Apr 2014 30 Jun 2014 10-K 14 Mar 2016
Q1 2014 -$22.9M -$10M -$3.37M -50.7% 01 Jan 2014 31 Mar 2014 10-K 14 Mar 2016
Q4 2013 -$19.5M -$8M -$1.78M -28.5% 01 Oct 2013 31 Dec 2013 10-K 16 Mar 2015
Q3 2013 -$17.8M $766K +$7.06M 01 Jul 2013 30 Sep 2013 10-K 16 Mar 2015
Q2 2013 -$24.8M -$5.67M +$1.12M +16.4% 01 Apr 2013 30 Jun 2013 10-K 16 Mar 2015
Q1 2013 -$25.9M -$6.63M -$2.45M -58.5% 01 Jan 2013 31 Mar 2013 10-K 16 Mar 2015
Q4 2012 -$23.5M -$6.23M -$447K -7.74% 01 Oct 2012 31 Dec 2012 10-K 17 Mar 2014
Q3 2012 -$23M -$6.29M +$44.5K +0.7% 01 Jul 2012 30 Sep 2012 10-K 17 Mar 2014
Q2 2012 -$23.1M -$6.79M -$1.65M -32.1% 01 Apr 2012 30 Jun 2012 10-K 17 Mar 2014
Q1 2012 -$21.4M -$4.19M +$199K +4.54% 01 Jan 2012 31 Mar 2012 10-K 17 Mar 2014
Q4 2011 -$21.6M -$5.78M 01 Oct 2011 31 Dec 2011 10-K 18 Mar 2013
Q3 2011 -$6.34M -$1.78M -39.1% 01 Jul 2011 30 Sep 2011 10-K 18 Mar 2013
Q2 2011 -$5.14M -$161K -3.23% 01 Apr 2011 30 Jun 2011 10-K 18 Mar 2013
Q1 2011 -$4.39M 01 Jan 2011 31 Mar 2011 10-K 18 Mar 2013
Q3 2010 -$4.56M 01 Jul 2010 30 Sep 2010 10-Q 07 Nov 2011
Q2 2010 -$4.98M 01 Apr 2010 30 Jun 2010 10-Q 05 Aug 2011

INOVIO PHARMACEUTICALS, INC. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$112M +$31.5M +21.9% 01 Jan 2024 31 Dec 2024 10-K 18 Mar 2025
2023 -$144M +$124M +46.2% 01 Jan 2023 31 Dec 2023 10-K 18 Mar 2025
2022 -$268M +$33.6M +11.2% 01 Jan 2022 31 Dec 2022 10-K 06 Mar 2024
2021 -$301M -$177M -143% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2024
2020 -$124M -$13M -11.7% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023
2019 -$111M -$17M -18.1% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022
2018 -$94.1M -$10.4M -12.5% 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021
2017 -$83.6M -$7.41M -9.72% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2020
2016 -$76.2M -$42M -122% 01 Jan 2016 31 Dec 2016 10-K 12 Mar 2019
2015 -$34.3M +$5.21M +13.2% 01 Jan 2015 31 Dec 2015 10-K 14 Mar 2018
2014 -$39.5M -$20M -102% 01 Jan 2014 31 Dec 2014 10-K 15 Mar 2017
2013 -$19.5M +$3.95M +16.8% 01 Jan 2013 31 Dec 2013 10-K 14 Mar 2016
2012 -$23.5M -$1.85M -8.57% 01 Jan 2012 31 Dec 2012 10-K 16 Mar 2015
2011 -$21.6M -$2.42M -12.6% 01 Jan 2011 31 Dec 2011 10-K 17 Mar 2014
2010 -$19.2M 01 Jan 2010 31 Dec 2010 10-K 18 Mar 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.